FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1966614045> ?p ?o ?g. }

• W1966614045 endingPage "10370" @default.
• W1966614045 startingPage "10370" @default.
• W1966614045 abstract "Epidermal growth factor receptor (EGFR) is the target of several clinically approved tyrosine kinase inhibitor (TKI) drugs including gefitinib and erlotinib in the treatment of cancer. Multiple mechanisms have been implicated in the clinical features of these drugs. However, little is known about the molecular mechanism of action of these drugs at the whole cell level. Here we applied a label-free biosensor-enabled dynamic mass redistribution (DMR) assay to assess the molecular mechanism of action of three EGFR inhibitors, gefitinib, erlotinib and AG1478, to alter the EGFR signaling in A431 and HT-29, two native cancer cell lines expressing the EGFR. The whole-cell DMR assays with the persistent inhibitor treatment showed that all inhibitors dose-dependently inhibited the EGFR signaling in both cell lines, but generally displayed higher potency in A431 than HT-29 cells. The DMR assays with the inhibitor washout showed that the washout unexpectedly increased the potency of gefitinib and AG-1478 to inhibit the EGFR signaling in A431, but slightly decreased the potency of all three inhibitors in HT29. The DMR assays under microfluidics showed that the removal of the inhibitors using buffer perfusion resulted in a time-dependent recovery of EGF signaling that is slower in A431 than HT-29 cells. In contrast, DMR assays under microfluidics showed that the removal of reversible competitive antagonists led to the full recovery of the signalling of two distinct G protein-coupled receptors (GPCRs), the β2-adrenergic receptor in A431 and the GPR35 in HT-29 cells. Together, our results suggest that for EGFR inhibitors their uptake and retention, rather than binding kinetics, dominate their label-free cell phenotypic efficacy; however, for GPCR antagonists the binding characteristics are critical to the inhibitory effects. This study also implicates the potential of DMR assays under different simulation conditions for elucidating the cell phenotypic pharmacology, in particular transporter-related drug resistance, of kinase inhibitor drugs." @default.
• W1966614045 created "2016-06-24" @default.
• W1966614045 creator A5040107793 @default.
• W1966614045 creator A5040502320 @default.
• W1966614045 creator A5086980197 @default.
• W1966614045 date "2013-01-01" @default.
• W1966614045 modified "2023-09-23" @default.
• W1966614045 title "Label-free cell phenotypic assessment of the molecular mechanism of action of epidermal growth factor receptor inhibitors" @default.
• W1966614045 cites W1550454373 @default.
• W1966614045 cites W1587498640 @default.
• W1966614045 cites W1805382234 @default.
• W1966614045 cites W1969792608 @default.
• W1966614045 cites W1970092877 @default.
• W1966614045 cites W1974024530 @default.
• W1966614045 cites W1974806896 @default.
• W1966614045 cites W1975826619 @default.
• W1966614045 cites W1996948818 @default.
• W1966614045 cites W1997233919 @default.
• W1966614045 cites W1998274141 @default.
• W1966614045 cites W2003984225 @default.
• W1966614045 cites W2005969139 @default.
• W1966614045 cites W2007139449 @default.
• W1966614045 cites W2012269590 @default.
• W1966614045 cites W2016408686 @default.
• W1966614045 cites W2016710415 @default.
• W1966614045 cites W2017785769 @default.
• W1966614045 cites W2019300759 @default.
• W1966614045 cites W2026293292 @default.
• W1966614045 cites W2028404470 @default.
• W1966614045 cites W2032429863 @default.
• W1966614045 cites W2034129064 @default.
• W1966614045 cites W2044634375 @default.
• W1966614045 cites W2046978350 @default.
• W1966614045 cites W2056237718 @default.
• W1966614045 cites W2061298242 @default.
• W1966614045 cites W2062866488 @default.
• W1966614045 cites W2065156829 @default.
• W1966614045 cites W2071289226 @default.
• W1966614045 cites W2088395718 @default.
• W1966614045 cites W2092187686 @default.
• W1966614045 cites W2103177188 @default.
• W1966614045 cites W2110335585 @default.
• W1966614045 cites W2122894850 @default.
• W1966614045 cites W2128307445 @default.
• W1966614045 cites W2130244550 @default.
• W1966614045 cites W2131361386 @default.
• W1966614045 cites W2135117965 @default.
• W1966614045 cites W2138515877 @default.
• W1966614045 cites W2154834806 @default.
• W1966614045 cites W2157824687 @default.
• W1966614045 cites W2161682775 @default.
• W1966614045 cites W2161821474 @default.
• W1966614045 cites W2163252214 @default.
• W1966614045 cites W2163885776 @default.
• W1966614045 cites W2168007598 @default.
• W1966614045 cites W2171108415 @default.
• W1966614045 cites W2323214517 @default.
• W1966614045 doi "https://doi.org/10.1039/c3ra40426a" @default.
• W1966614045 hasPublicationYear "2013" @default.
• W1966614045 type Work @default.
• W1966614045 sameAs 1966614045 @default.
• W1966614045 citedByCount "18" @default.
• W1966614045 countsByYear W19666140452013 @default.
• W1966614045 countsByYear W19666140452014 @default.
• W1966614045 countsByYear W19666140452015 @default.
• W1966614045 countsByYear W19666140452016 @default.
• W1966614045 countsByYear W19666140452017 @default.
• W1966614045 countsByYear W19666140452018 @default.
• W1966614045 countsByYear W19666140452020 @default.
• W1966614045 countsByYear W19666140452022 @default.
• W1966614045 crossrefType "journal-article" @default.
• W1966614045 hasAuthorship W1966614045A5040107793 @default.
• W1966614045 hasAuthorship W1966614045A5040502320 @default.
• W1966614045 hasAuthorship W1966614045A5086980197 @default.
• W1966614045 hasBestOaLocation W19666140452 @default.
• W1966614045 hasConcept C104317684 @default.
• W1966614045 hasConcept C111472728 @default.
• W1966614045 hasConcept C121332964 @default.
• W1966614045 hasConcept C127716648 @default.
• W1966614045 hasConcept C138885662 @default.
• W1966614045 hasConcept C170493617 @default.
• W1966614045 hasConcept C185592680 @default.
• W1966614045 hasConcept C202751555 @default.
• W1966614045 hasConcept C2776120743 @default.
• W1966614045 hasConcept C2779438470 @default.
• W1966614045 hasConcept C2780791683 @default.
• W1966614045 hasConcept C502942594 @default.
• W1966614045 hasConcept C55493867 @default.
• W1966614045 hasConcept C62520636 @default.
• W1966614045 hasConcept C86803240 @default.
• W1966614045 hasConcept C89611455 @default.
• W1966614045 hasConcept C95444343 @default.
• W1966614045 hasConceptScore W1966614045C104317684 @default.
• W1966614045 hasConceptScore W1966614045C111472728 @default.
• W1966614045 hasConceptScore W1966614045C121332964 @default.
• W1966614045 hasConceptScore W1966614045C127716648 @default.
• W1966614045 hasConceptScore W1966614045C138885662 @default.
• W1966614045 hasConceptScore W1966614045C170493617 @default.

• next